00:14 , Jun 4, 2019 |  BC Innovations  |  Distillery Therapeutics

PDE-1 inhibition could treat heart failure

DISEASE CATEGORY: Cardiovascular INDICATION: Heart failure Mouse studies suggest PDE-1 inhibitors could help treat a subtype of heart failure. In a mouse model of cardiac proteinopathy-induced heart failure with preserved ejection fraction, a tool compound...
23:13 , Jan 25, 2018 |  BC Innovations  |  Strategy

Takeda rides Denali’s ATV

In its deal with Denali, Takeda has not only boosted its CNS pipeline, but also gained access to a delivery technology that could open the door to a host of CNS targets only druggable with...
21:39 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

Intra-Cellular begins Phase III trial of ITI-214 in PD

In October, Intra-Cellular Therapies Inc. (NASDAQ:ITCI) began the Phase I/II ITI-214-105 trial of ITI-214 to treat idiopathic Parkinson's disease. The double-blind, U.S. trial will evaluate once-daily oral doses of 1, 3 or 10 mg ITI-214...
08:00 , Nov 24, 2014 |  BC Week In Review  |  Company News

Intra-Cellular, Takeda deal

Intra-Cellular and Takeda mutually terminated a 2011 deal granting the pharma worldwide rights to develop and commercialize Intra-Cellular’s phosphodiesterase-1 (PDE-1) inhibitors. The biotech declined to disclose whether there was a termination fee. The deal included...
08:00 , Feb 25, 2013 |  BC Week In Review  |  Clinical News

ITI-214: Phase I data

A double-blind, placebo-controlled Phase I trial in 70 healthy volunteers showed that single ascending-doses of oral ITI-214 were well tolerated. Intra-Cellular declined to disclose next steps. In 2011, the company partnered with Takeda to develop...
08:00 , Mar 7, 2011 |  BC Week In Review  |  Company News

Intra-Cellular, Takeda deal

Intra-Cellular and Takeda partnered to develop and commercialize Intra-Cellular's preclinical phosphodiesterase-1 (PDE-1) inhibitors. The lead compound, which is part of Intra-Cellular's ITI-002 program, is being developed to treat cognitive impairment associated with schizophrenia. Intra-Cellular will...
01:54 , Mar 3, 2011 |  BC Extra  |  Company News

Intra-Cellular, Takeda in schizophrenia deal

Intra-Cellular Therapies Inc. (New York, N.Y.) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) partnered to develop and commercialize Intra-Cellular's preclinical phosphodiesterase-1 (PDE-1) inhibitors to treat cognitive impairment associated with schizophrenia. Intra-Cellular will receive an undisclosed upfront...
07:00 , Oct 18, 2010 |  BC Week In Review  |  Clinical News

Intra-Cellular preclinical data

In a mouse model of PD, oral ITI-002 in combination with L-dopa restored normal motor function and reversed akinesia and catalepsy that were induced by the generic typical antipsychotic haloperidol. Furthermore, the oral phosphodiesterase-1 (PDE-1)...